GlassScriptPhysician profile
Jenna Tong
NPI 1407331069
$3,240.75
in general payments reported to CMS, 2019-2025
26 companies · $257 in 2025
The $257 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,563 · 2022: $952 · 2023: $252 · 2024: $216 · 2025: $257.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $726.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $725.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $393.98 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $303.45 | 2021-2022 | |
| Grifols USA, LLC | $291.49 | 2021-2022 | |
| Philips North America LLC | $286.89 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $276.83 | 2021-2024 | Glassia |
| Astrazeneca Pharmaceuticals LP | $269.34 | 2021-2022 | |
| Harmony Biosciences LLC | $263.21 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $259.81 | 2022-2025 | Dupixent |
| Glaxosmithkline, LLC. | $257.85 | 2021-2025 | Nucala |
| Jazz Pharmaceuticals INC. | $98.75 | 2021-2022 | |
| Alk-Abello, INC | $96.14 | 2022-2025 | Grastek, Odactra, Ragwitek |
| Phathom Pharmaceuticals, INC. | $52.82 | 2025 | Voquezna |
| Mylan Specialty L.P. | $46.64 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $42.00 | 2021-2022 | |
| United Therapeutics Corporation | $39.91 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $36.12 | 2021 | |
| Electromed, INC. | $33.34 | 2021-2022 | |
| Medtronic, INC. | $31.51 | 2024 | Propel |
| Hikma Pharmaceuticals USA | $31.47 | 2023 | Ryaltris |
| Cochlear Americas | $21.78 | 2023 | Cochlear Nucleus Ci632 Cochlear Implant With Slim Modiolar Electrode, Osia Osi300 Implant, Baha |
| Insmed, INC. | $21.75 | 2022 | |
| Mallinckrodt Hospital Products INC. | $18.89 | 2022 | |
| Novo Nordisk INC | $18.68 | 2025 | Ozempic, Rybelsus |
| Genzyme Corporation | $17.67 | 2024 | |
| Merck Sharp & Dohme LLC | $17.48 | 2023 | |
| Circassia INC. | $12.95 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jenna Tong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.